FierceBiotech 2026-02-17 Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering
FierceBiotech 2026-02-17 Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push
FierceBiotech 2026-02-17 Novocure gets FDA nod for tumor-treating electric fields targeting pancreatic cancer
FierceBiotech 2026-02-17 Gilead’s latest synthetic lethal therapy comes via $1.5B deal with China’s Genhouse
FierceBiotech 2026-02-16 Biopharma funding to experience 'continued, albeit disciplined' recovery in 2026: PitchBook
FierceBiotech 2026-02-14 'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments
FierceBiotech 2026-02-13 With the FDA's Moderna decision, vaccine makers face increasingly uncertain regulatory environment
FierceBiotech 2026-02-13 After R&D head exits, Immunocore CEO pairs ambition with caution for growing cancer portfolio
FierceBiotech 2026-02-13 Integra LifeSciences cuts roles as 65 staffers impacted from Princeton, N.J., site
FierceBiotech 2026-02-13 Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans
FierceBiotech 2026-02-13 'When the markets opened, we were ready': Why biotech IPOs are back for 2026
FierceBiotech 2026-02-12 Icon shares plummet after CRO reveals accounting investigation, pulls 2025 guidance